Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Status:
Completed
Trial end date:
2016-08-30
Target enrollment:
Participant gender:
Summary
This is a Phase I study, which means that the goal is to see if the study treatment is safe.
The purpose of this study is to test the safety of Lenalidomide at different dose levels, and
to test the safety of Lenalidomide alone or in combination with Rituximab (also known as
Rituxan®).
Phase:
Phase 1
Details
Lead Sponsor:
James Rubenstein University of California, San Francisco